How to Add Hormone Therapy to an Existing Practice

Why This Expansion Converts Better Than Almost Any Other

Most practices considering a hormone therapy expansion already have the patients. A med spa's core demographic overlaps almost completely with the hormone optimization patient. A primary care panel contains a substantial number of patients whose fatigue, weight changes, and low mood have a hormonal component that a fifteen-minute insurance-reimbursed visit was never going to properly address. A weight loss practice is already treating patients whose metabolic picture is inseparable from their hormonal one.

The commercial advantage is that this expansion does not require patient acquisition. It requires a clinical conversation with patients who are already in the building and already trust the practice — which converts at rates that no advertising channel matches.

For the full market analysis behind this service category, see The Hormone Optimization Clinic Business Opportunity.

The Prescribing Question, Answered by Practice Type

What this expansion requires operationally depends entirely on who in the practice holds prescribing authority.

Practices With a Physician or Prescribing NP Already

A primary care practice, med spa with a medical director, or wellness practice with an NP on staff has the most direct path. The prescribing authority already exists. What needs to be built is the clinical protocol, the monitoring schedule, the documentation standard, and — if testosterone will be dispensed or administered on site — DEA registration if the practice does not already hold it.

Practices Without Prescribing Authority

A practice without a prescribing clinician needs to add one, and what that requires varies by state. The AANP state practice environment map sets out which states permit nurse practitioners to prescribe independently, including controlled substances, and which require a collaborative or supervisory physician relationship. In a full practice state, hiring or contracting an NP may be sufficient. In a restricted practice state, a physician relationship is required, which changes both cost and recruiting difficulty.

The Clinical Infrastructure the Expansion Actually Needs

Adding hormone therapy correctly means adopting a monitoring protocol, not just a prescribing capability. The AUA testosterone deficiency guideline establishes the framework most clinics build from — including the requirement for confirmed low testosterone measured appropriately before therapy begins, baseline hematologic assessment, PSA screening in men over 40, and ongoing reassessment at defined intervals during treatment.

For an existing practice, the practical question is whether the current lab workflow can support that cadence. A practice already drawing blood in-office has most of what it needs. A practice that refers all labs out will need to decide whether to build draw capability or accept the monitoring compliance loss that comes with sending patients elsewhere.

Documentation is the other piece. Controlled substance prescribing carries record-keeping requirements that a practice not currently prescribing them may not have infrastructure for. This is worth resolving before the first prescription rather than retrofitting after.

The Conversation That Converts Existing Patients

The most common failure in this expansion is announcing the new service rather than integrating it into clinical workflow. A practice-wide email announcing hormone therapy produces a trickle of interest. Expanding the intake and annual review process to include a brief hormonal health screen produces a steady, clinically grounded stream of appropriate candidates.

The mechanism is straightforward: patients who report fatigue, declining libido, changes in body composition, mood disruption, or poor recovery get offered a hormone panel as part of the clinical workup rather than as an upsell. The lab result then drives the conversation. A patient looking at their own confirmed low testosterone alongside symptoms they have been describing for months is not being sold anything — they are receiving a clinical explanation they had not previously been offered.

This is also the framing that keeps the expansion clinically defensible. Therapy follows confirmed deficiency and documented symptoms, which is both the correct clinical standard and the structure that protects the practice.

Realistic Revenue Impact

A practice with 300 active patients that converts 8 to 12 percent to hormone therapy enrollment adds roughly 24 to 36 enrolled patients. At the $2,600 to $5,800 annual revenue range typical for this service, that represents approximately $60,000 to $200,000 in added annual recurring revenue from patients the practice already had.

These are illustrative planning benchmarks — actual results depend on patient demographics, conversion execution, pricing, and retention. The conversion rate in particular varies widely based on how well the clinical conversation is integrated into existing workflow versus bolted on.

The Women's Hormone Opportunity Most Practices Skip

Practices adding hormone therapy default overwhelmingly to men's TRT, and in doing so leave the larger and less contested half of the opportunity untouched. A med spa or primary care practice with a predominantly female patient panel that adds only testosterone therapy has built a service for the smaller share of its own patient base.

The perimenopausal and menopausal patient is, in most practices, already present in volume and already describing the symptoms — disrupted sleep, cognitive fog, mood changes, weight redistribution, declining libido — that a hormonal workup would explain. What she has usually not been offered is a comprehensive hormonal assessment, because a standard visit does not have room for one and because conventional management of these symptoms has historically been fragmented across specialists.

Operationally, adding women's hormone services alongside men's requires the same prescribing authority and much of the same monitoring infrastructure, with a different protocol set and a meaningfully different consultation conversation. The incremental build cost is modest relative to the addressable patient volume it unlocks. Practices that scope this expansion as hormone optimization broadly, rather than TRT specifically, consistently reach their revenue targets faster than those that launch men's services first and treat women's as a later phase.

Sequencing the Expansion Correctly

The order in which this expansion is built determines how quickly it produces revenue. The pattern that works: confirm prescribing authority and any required DEA registration first, since everything downstream depends on it and the timelines are outside the practice's control. Build the clinical protocol and monitoring workflow second, with the prescribing clinician's direct input rather than adapted from a template. Train the patient-facing team on the screening conversation third. Only then begin actively promoting the service.

Practices that invert this — announcing the service before the protocol and monitoring workflow are settled — generate interest they cannot convert cleanly, and spend the first two months improvising clinical process in front of real patients. The delay in going public feels costly in the moment and consistently pays for itself in the first quarter.

ACG's optimization engagement for existing practices begins with a structured audit identifying which expansion fits the practice's actual patient base and infrastructure. To learn more, visit altosconsultinggroup.com/existing-clinic-growth. To start the conversation, visit altosconsultinggroup.com/survey.

Frequently Asked Questions

Can a med spa add testosterone therapy?

Yes, provided the practice has or adds a clinician with appropriate prescribing authority for controlled substances in that state, and provided the clinical protocol and monitoring infrastructure are built to standard. Med spas are among the better-positioned practice types for this expansion because the patient demographic overlaps heavily and the premium cash-pay payment model is already established with the patient base.

How long does it take to add hormone therapy to an existing practice?

For a practice with prescribing authority already in place, four to eight weeks is realistic once protocol documentation, monitoring workflow, and any required DEA registration are complete. For a practice adding a prescribing clinician, the timeline extends to eight to twelve weeks or longer depending on how quickly that clinician can be recruited and credentialed.

Do I need a separate business entity to add hormone therapy?

Often not, if the existing practice already has an appropriate structure and prescribing clinician. A practice owned by a non-clinician that is adding prescribing services for the first time may need to restructure into an MSO arrangement. This determination should be made with healthcare counsel reviewing the specific existing entity setup rather than assumed either way.

What is the most common mistake practices make with this expansion?

Treating monitoring as optional. A practice that prescribes hormone therapy without building the lab cadence into its workflow is creating both a clinical risk and a business problem — monitoring is the mechanism that drives retention, and a practice that skips it tends to see patients drift away within the first year without understanding why.